从iPSC衍生的治疗细胞产品的符合GMP的制造:技术,应用,风险和局限性
Alexandra Haase1, Arjang Ruhparwar1, Ulrich Martin1
1Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiothoracic, Transplantation and Vascular Surgery, REBIRTH Cluster of Excellence, Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), Member of the German Center for Lung Research (DZL), Hannover Medical School, Germany.
Advanced drug delivery reviews
|December 4, 2025
概括
根据良好的制造实践 (GMP) 制造诱导多能干细胞 (iPSC) 对再生医学至关重要. 必须克服符合GMP的挑战,包括成本和监管,以便iPSC疗法达到患者.
科学领域:
- 再生医学是一种再生医学.
- 干细胞生物学 干细胞生物学
- 生物技术是生物技术.
背景情况:
- 诱导多能干细胞 (iPSCs) 对再生医学具有重大前景.
- 治疗应用需要在严格的良好制造实践 (GMP) 条件下进行iPSC生产.
- 当前的制造工艺在满足监管标准方面面临着挑战.
研究的目的:
- 审查美国,欧洲和日本的监管格局,以符合GMP的iPSC生产.
- 确定从iPSCs衍生的先进疗法药物 (ATMP) 制造当前的挑战和机遇.
- 突出关键的质量属性,以确保基于iPSC的疗法的安全性和有效性.
主要方法:
- 对全球主要市场的监管准则和当局的审查.
- 对符合GMP的iPSC重编程,表征和扩展的挑战进行分析.
- 讨论质量控制措施,包括不育,身份和遗传完整性.
主要成果:
- 显著的监管障碍和高成本阻碍了iPSC疗法的临床转化.
- 需要定义的培养介质和自动化的封闭系统,以实现一致的GMP生产.
- 细胞系特异性变异对自身的iPSC产品开发构成挑战.
结论:
- 克服制造和监管方面的挑战对于基于iPSC的再生医学临床成功至关重要.
- 通过严格的控制来确保产品质量,安全性和有效性至关重要.
- 成功生产符合GMP的iPSC将为各种疾病提供新的治疗选择.
相关概念视频
Induced Pluripotent Stem Cells
5.3K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
5.3K
Induced Pluripotent Stem Cells
27.2K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
27.2K
iPS Cell Differentiation
3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
EPS and iPS Cells in Disease Research
3.3K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.3K
Embryonic Stem Cells
4.6K
Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
4.6K


